Given the increasing age of patients diagnosed with HCC, and the fact that viral cirrhosis is decreasing and metabolic dysfunction-associated steatohepatitis is increasing as a cause of liver cancer, the indications for VEGF-free regimens may increase. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.